RT Journal Article
T1 Emerging role of microRNAs in dilated cardiomyopathy: evidence regarding etiology.
A1 Calderon-Dominguez, Maria
A1 Belmonte, Thalia
A1 Quezada-Feijoo, Maribel
A1 Ramos-Sanchez, Monica
A1 Fernandez-Armenta, Juan
A1 Perez-Navarro, Amparo
A1 Cesar, Sergi
A1 Peña-Peña, Luisa
A1 Vea, Angela
A1 Llorente-Cortes, Vicenta
A1 Mangas, Alipio
A1 de Gonzalo-Calvo, David
A1 Toro, Rocio
K1 Coronary artery disease
K1 Cardiovascular diseases
K1 Dilatation
K1 Cardiomyopathies
K1 Heart diseases
AB Dilated cardiomyopathy (DCM) is a heart muscle disease characterized by ventricular dilation and systolic dysfunction in the absence of abnormal loading conditions or coronary artery disease. This cardiac disorder is a major health problem due to its high prevalence, morbidity, and mortality. DCM is a complex disease with a common phenotype but heterogeneous pathological mechanisms. Early etiological diagnosis and prognosis stratification is crucial for the clinical management of the patient. Advances in imaging technology and genetic tests have provided useful tools for clinical practice. Nevertheless, the assessment of the disease remains challenging. Novel noninvasive indicators are still needed to assist in decision-making. microRNAs (miRNAs), a group of small noncoding RNAs, have been identified as key mediators of cell biology. They are found in a stable form in body fluids and their concentration is altered in response to stress. Previous research has suggested that the miRNA signature constitutes a novel source of noninvasive biomarkers for a wide array of cardiovascular diseases. Specifically, several studies have reported the potential role of miRNAs as clinical indicators among the etiologies of DCM. However, this field has not been reviewed in detail. Here, we summarize the evidence of intracellular and circulating miRNAs in DCM and their usefulness in the development of novel diagnostic, prognostic and therapeutic approaches, with a focus on DCM etiology. Although the findings are still preliminary, due to methodological and technical limitations and the lack of robust population-based studies, miRNAs constitute a promising tool to assist in the clinical management of DCM.
PB Elsevier
YR 2019
FD 2019-08-20
LK http://hdl.handle.net/10668/14491
UL http://hdl.handle.net/10668/14491
LA en
NO Calderon-Dominguez M, Belmonte T, Quezada-Feijoo M, Ramos-Sánchez M, Fernández-Armenta J, Pérez-Navarro A, et al. Emerging role of microRNAs in dilated cardiomyopathy: evidence regarding etiology. Transl Res. 2020 Jan;215:86-101
NO This work was co-financed by the by the Ministry of Health of the Junta de Andalucıa, within the framework of the “Integrated Territorial Initiative” with file number PI-0048-2017, and under the European Regional Development Fund (ERDF), within the Operational Program of Andalusia ERDF 2014-2020 and funded by the Ministry of Health of the Junta de Andalucıa, within the framework of the “grants for the financing of biomedical research, development and innovation in health sciences in Andalusia, for the year 2018” with file number P-0136-2018. DdG-C is a recipient of a Juan de la Cierva-incorporacion grant from the Ministerio de Economıa y Competitividad (IJCI-2016-29393). CIBER Cardiovascular (CB16/11/00403 to DdG-C and VL-C) is a project of the Instituto de Salud Carlos III.
DS RISalud
RD Apr 7, 2025